UCB SA (UCBJF)
USD 150.7
(-5.46%)
USD 150.7
(-5.46%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.56 Billion EUR | -3.53% |
| 2022 | 6.8 Billion EUR | 16.83% |
| 2021 | 5.82 Billion EUR | -3.69% |
| 2020 | 6.04 Billion EUR | 48.5% |
| 2019 | 4.07 Billion EUR | -4.39% |
| 2018 | 4.25 Billion EUR | 1.87% |
| 2017 | 4.18 Billion EUR | -11.7% |
| 2016 | 4.73 Billion EUR | -12.48% |
| 2015 | 5.41 Billion EUR | 1.96% |
| 2014 | 5.3 Billion EUR | 0.02% |
| 2013 | 5.3 Billion EUR | 11.29% |
| 2012 | 4.76 Billion EUR | 9.46% |
| 2011 | 4.35 Billion EUR | -0.5% |
| 2010 | 4.37 Billion EUR | -6.93% |
| 2009 | 4.7 Billion EUR | -14.6% |
| 2008 | 5.5 Billion EUR | 4.08% |
| 2007 | 5.29 Billion EUR | -7.5% |
| 2006 | 5.72 Billion EUR | 147.83% |
| 2005 | 2.3 Billion EUR | -32.29% |
| 2004 | 3.4 Billion EUR | 160.76% |
| 2003 | 1.3 Billion EUR | 23.83% |
| 2002 | 1.05 Billion EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 6.67 Billion EUR | 0.0% |
| 2024 Q1 | 6.67 Billion EUR | 1.71% |
| 2023 Q2 | 6.33 Billion EUR | -0.02% |
| 2023 FY | 6.56 Billion EUR | -3.53% |
| 2023 Q3 | 6.56 Billion EUR | 3.55% |
| 2023 Q4 | 6.56 Billion EUR | 0.0% |
| 2023 Q1 | 6.34 Billion EUR | -6.82% |
| 2022 Q2 | 7.39 Billion EUR | 0.0% |
| 2022 Q4 | 6.8 Billion EUR | 0.0% |
| 2022 FY | 6.8 Billion EUR | 16.83% |
| 2022 Q1 | 7.39 Billion EUR | 26.91% |
| 2022 Q3 | 6.8 Billion EUR | -7.94% |
| 2021 Q1 | 5.36 Billion EUR | -11.23% |
| 2021 Q2 | 5.36 Billion EUR | 0.0% |
| 2021 Q4 | 5.82 Billion EUR | 0.0% |
| 2021 Q3 | 5.82 Billion EUR | 8.49% |
| 2021 FY | 5.82 Billion EUR | -3.69% |
| 2020 Q4 | 6.04 Billion EUR | 0.0% |
| 2020 Q1 | 6.12 Billion EUR | 50.52% |
| 2020 Q3 | 6.04 Billion EUR | -1.34% |
| 2020 FY | 6.04 Billion EUR | 48.5% |
| 2020 Q2 | 6.12 Billion EUR | 0.0% |
| 2019 Q3 | 4.07 Billion EUR | 0.27% |
| 2019 FY | 4.07 Billion EUR | -4.39% |
| 2019 Q1 | 4.06 Billion EUR | -4.65% |
| 2019 Q2 | 4.06 Billion EUR | 0.0% |
| 2019 Q4 | 4.07 Billion EUR | 0.0% |
| 2018 Q3 | 4.25 Billion EUR | 0.12% |
| 2018 Q1 | 4.25 Billion EUR | 1.75% |
| 2018 FY | 4.25 Billion EUR | 1.87% |
| 2018 Q4 | 4.25 Billion EUR | 0.0% |
| 2018 Q2 | 4.25 Billion EUR | 0.0% |
| 2017 Q2 | 4.27 Billion EUR | 0.0% |
| 2017 Q3 | 4.18 Billion EUR | -2.15% |
| 2017 Q4 | 4.18 Billion EUR | 0.0% |
| 2017 FY | 4.18 Billion EUR | -11.7% |
| 2017 Q1 | 4.27 Billion EUR | -9.76% |
| 2016 Q1 | 5.12 Billion EUR | -5.25% |
| 2016 FY | 4.73 Billion EUR | -12.48% |
| 2016 Q4 | 4.73 Billion EUR | 0.0% |
| 2016 Q3 | 4.73 Billion EUR | -7.63% |
| 2016 Q2 | 5.12 Billion EUR | 0.0% |
| 2015 Q1 | 5.43 Billion EUR | 2.36% |
| 2015 Q3 | 5.41 Billion EUR | -0.41% |
| 2015 FY | 5.41 Billion EUR | 1.96% |
| 2015 Q4 | 5.41 Billion EUR | 0.0% |
| 2015 Q2 | 5.43 Billion EUR | 0.02% |
| 2014 Q2 | 5.06 Billion EUR | 0.0% |
| 2014 Q1 | 5.06 Billion EUR | -4.49% |
| 2014 FY | 5.3 Billion EUR | 0.02% |
| 2014 Q4 | 5.3 Billion EUR | 0.91% |
| 2014 Q3 | 5.25 Billion EUR | 3.77% |
| 2013 Q2 | 5.06 Billion EUR | 0.0% |
| 2013 Q1 | 5.06 Billion EUR | 6.17% |
| 2013 Q4 | 5.3 Billion EUR | -2.43% |
| 2013 FY | 5.3 Billion EUR | 11.29% |
| 2013 Q3 | 5.43 Billion EUR | 7.43% |
| 2012 FY | 4.76 Billion EUR | 9.46% |
| 2012 Q2 | 4.61 Billion EUR | 0.0% |
| 2012 Q4 | 4.76 Billion EUR | 0.0% |
| 2011 Q4 | 4.35 Billion EUR | 0.0% |
| 2011 Q2 | 3.75 Billion EUR | 0.0% |
| 2011 FY | 4.35 Billion EUR | -0.5% |
| 2010 Q4 | 4.37 Billion EUR | 0.0% |
| 2010 FY | 4.37 Billion EUR | -6.93% |
| 2010 Q2 | 5.26 Billion EUR | 0.0% |
| 2009 Q4 | 4.7 Billion EUR | 0.0% |
| 2009 FY | 4.7 Billion EUR | -14.6% |
| 2008 FY | 5.5 Billion EUR | 4.08% |
| 2007 FY | 5.29 Billion EUR | -7.5% |
| 2006 FY | 5.72 Billion EUR | 147.83% |
| 2005 FY | 2.3 Billion EUR | -32.29% |
| 2004 FY | 3.4 Billion EUR | 160.76% |
| 2003 FY | 1.3 Billion EUR | 23.83% |
| 2002 FY | 1.05 Billion EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Qrons Inc. | 1.48 Million USD | -440817.759% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -8661.345% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -12959.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -11022.775% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -14685777.931% |
| BioStem Technologies, Inc. | 15.9 Million USD | -41170.905% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -8957.416% |
| Skye Bioscience, Inc. | 14.07 Million USD | -46545.062% |
| Rebus Holdings, Inc. | 5.24 Million USD | -125119.382% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -69243.49% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -23927286.724% |
| Neon Bloom, Inc. | 1.22 Million USD | -535206.672% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -811478.721% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -3263688.063% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -12214.042% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -68403.287% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1556944.178% |
| SQZ Biotechnologies Company | 50.03 Million USD | -13017.768% |
| Intellipharmaceutics International Inc. | 12 Million USD | -54560.066% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -170330.469% |
| Mesoblast Limited | 188.44 Million USD | -3383.251% |
| Marizyme, Inc. | 26.67 Million USD | -24506.654% |
| Genus plc | 485 Million USD | -1253.402% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -112246.839% |
| Pharming Group N.V. | 244.07 Million USD | -2589.359% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -326446.044% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -260756.295% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -172636.842% |
| ContraFect Corporation | 32.53 Million USD | -20077.677% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -331196.295% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -171389.123% |
| IMV Inc. | 37.93 Million USD | -17204.288% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -55630.101% |
| MultiCell Technologies, Inc. | 1617.67 USD | -405768690.915% |
| ONE Bio Corp. | 27.49 Million USD | -23772.728% |
| Accustem Sciences Inc. | 1.07 Million USD | -608106.338% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -8378.758% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -310244.485% |
| Q BioMed Inc. | 8.13 Million USD | -80608.831% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -7814.632% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -127454.515% |
| Biomind Labs Inc. | 1.49 Million USD | -437905.301% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -5428.872% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -72493.001% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -35567.293% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -457684.96% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -4619344.738% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -114139.549% |
| GB Sciences, Inc. | 5.41 Million USD | -121061.623% |
| Alpha Cognition Inc. | 7.16 Million USD | -91514.893% |
| HST Global, Inc. | 593.59 Thousand USD | -1105708.188% |
| CSL Limited | 18.62 Billion USD | 64.749% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -521186.252% |
| Halberd Corporation | 728.71 Thousand USD | -900658.729% |
| Enzolytics Inc. | 365.26 Million USD | -1697.032% |
| Agentix Corp. | 2.51 Million USD | -261356.132% |
| Resverlogix Corp. | 67.39 Million USD | -9639.45% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -782509.94% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | -1375.219% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -382863.827% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -26425.47% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -55045.294% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -178991.577% |
| AVAX Technologies, Inc. | 3.99 Million USD | -164257.013% |
| Zenith Capital Corp. | 27.56 Thousand USD | -23809251.083% |
| Genscript Biotech Corporation | 1.32 Billion USD | -395.07% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2750325.302% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -175675.633% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -964011.663% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -241967.442% |
| Kadimastem Ltd | 3.5 Million USD | -187182.428% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -9807307.85% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1412427.249% |
| LadRx Corporation | 2.2 Million USD | -298192.046% |
| Cell Source, Inc. | 15.8 Million USD | -41426.658% |
| Regen BioPharma, Inc. | 5.45 Million USD | -120172.295% |
| Regen BioPharma, Inc. | 5.45 Million USD | -120172.295% |
| NovAccess Global Inc. | 7.86 Million USD | -83403.674% |
| Affymax, Inc. | 8.87 Million USD | -73893.913% |
| Itoco Inc. | 1.65 Million USD | -396959.918% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -319850.867% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -108413.804% |
| Mobile Lads Corp. | 1.31 Million USD | -499634.678% |
| CytoDyn Inc. | 127.89 Million USD | -5032.375% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -15703624.969% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -418956.204% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -59328.051% |
| SYBLEU INC | 681.41 Thousand USD | -963192.453% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -107472.963% |
| International Stem Cell Corporation | 5.27 Million USD | -124288.857% |
| Bioxytran, Inc. | 3.24 Million USD | -201900.308% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1048782.327% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -142066.391% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -15911.318% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -29381.249% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -323986.212% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -119724.754% |
| Neutra Corp. | 973.52 Thousand USD | -674148.019% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -22522.781% |
| PureTech Health plc | 125.58 Million USD | -5126.822% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -174608.055% |
| IXICO plc | 1.9 Million USD | -345320.599% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -31874.28% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -6252.832% |
| CSL Limited | 18.62 Billion USD | 64.749% |
| Cellectis S.A. | 249.36 Million USD | -2532.24% |